Akeso (AKESF) said its experimental lung cancer treatment ivonescimab improved overall survival compared with a widely used ...

Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an ...

Substantial EFS improvement with selpercatinib in RET fusion-positive disease ...

At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various ...

June 1 (Reuters) - Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients live 15% longer than ...

Thanks to recent therapy advances, the lung cancer mortality rate has declined and survival rates have improved. Many factors influence the likelihood of a lung cancer cure or long-term survival, ...

By Siddhi Mahatole May 21 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment ...

Breathing in wildfire pollution may make it harder for people with lung cancer to survive, according to a new study from UC Davis Comprehensive Cancer Center researchers. Wildfire-related air ...

Lung cancer is the leading cause of cancer death around the world, but it can be treated effectively if those most susceptible know their risk. To help individuals understand lung cancer and if they ...